Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Reciprocal regulation between the molecular clock and kidney injury

  • Rey-Serra, Carlos
  • Tituaña, Jessica
  • Lin, Terry
  • Herrero, José Ignacio
  • Miguel, Verónica
  • Barbas, Coral
  • Meseguer, Anna
  • Ramos, Ricardo
  • Chaix, Amandine
  • Panda, Satchidananda
  • Lamas Peláez, Santiago
Tubulointerstitial fibrosis is the common pathological substrate for many etiologies leading to chronic kidney disease. Although perturbations in the circadian rhythm have been associated with renal disease, the role of the molecular clock in the pathogenesis of fibrosis remains incompletely understood. We investigated the relationship between the molecular clock and renal damage in experimental models of injury and fibrosis (unilateral ureteral obstruction, folic acid, and adenine nephrotoxicity), using genetically modified mice with selective deficiencies of the clock components Bmal1, Clock, and Cry. We found that the molecular clock pathway was enriched in damaged tubular epithelial cells with marked metabolic alterations. In human tubular epithelial cells, TGFβ significantly altered the expression of clock components. Although Clock played a role in the macrophage-mediated inflammatory response, the combined absence of Cry1 and Cry2 was critical for the recruitment of neutrophils, correlating with a worsening of fibrosis and with a major shift in the expression of metabolism-related genes. These results support that renal damage disrupts the kidney peripheral molecular clock, which in turn promotes metabolic derangement linked to inflammatory and fibrotic responses., This work was supported by grants from the Ministerio de Ciencia e Innovación PID2019-104233RB-100/AEI/10.13039/501100011033 (S Lamas), Instituto de Salud Carlos III REDinREN RD12/0021/0009 and RD16/0009/0016 (S Lamas), Comunidad de Madrid “NOVELREN” B2017/BMD-3751 and INNOREN P2022/BMD-7221 (S Lamas and C Barbas), and Fundación Renal “Iñigo Alvarez de Toledo” (S Lamas), all from Spain. C Rey-Serra has been the recipient of an FPI research training contract from the Spanish Research State Agency (BES-2016-076735). The CBMSO receives institutional support from Fundación “Ramón Areces.”, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Therapeutic variability in adult minimal change disease and focal segmental glomerulosclerosis

  • Fernández-Juárez, Gema|||0000-0001-6641-7763
  • Villacorta, Javier
  • Ruiz-Roso, Gloria
  • Panizo, Nayara|||0000-0002-1329-2976
  • Martinez-Marín, Isabel
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Arrizabalaga, Pilar|||0000-0002-9205-2646
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Vaca, Marco
  • Rodríguez García, Eva
  • Cobelo, Carmen
  • Fernandez, Loreto
  • Ávila, Ana
  • Praga, Manuel|||0000-0001-9270-1071
  • Quereda, Carlos
  • Ortiz, Alberto|||0000-0002-9805-9523
Variability in the management of glomerulonephritis may negatively impact efficacy and safety. However, there are little/no data on actual variability in the treatment of minimal change disease (MCD)/focal segmental glomerulosclerosis (FSGS) in adults. We assessed Spanish practice patterns for the management of adult nephrotic syndrome due to MCD or FSGS. The absence of reasonably good evidence on treatment for a disease often increases the variability substantially. Identification of evidence-practice gaps is the first necessary step in the knowledge-to-action cyclical process. We aim to analyse the real clinical practice in adults in hospitals in Spain and compare this with the recently released Kidney Disease: Improving Global Outcomes clinical practice guideline for glomerulonephritis. Participating centres were required to include all adult patients (age.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Acute pancreatitis promotes the generation of two different exosome populations

  • Jiménez-Alesanco, A.
  • Marcuello, M.
  • Pastor-Jiménez, M.
  • López-Puerto, L.
  • Bonjoch, Laia|||0000-0002-3351-0037
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Carrascal Pérez, Montserrat|||0000-0002-0205-2176
  • Abian, Joaquin|||0000-0003-2823-5429
  • de-Madaria, Enrique|||0000-0002-2412-9541
  • Closa Autet, Daniel|||0000-0003-3797-3095
Exosomes are small extracellular vesicles that act as intercellular messengers. Previous studies revealed that, during acute pancreatitis, circulating exosomes could reach the alveolar compartment and activate macrophages. However, proteomic analysis suggested that the most likely origin of these exosomes could be the liver instead of the pancreas. The present study aimed to characterize the exosomes released by pancreas to pancreatitis-associated ascitic fluid (PAAF) as well as those circulating in plasma in an experimental model of taurocholate-induced acute pancreatitis in rats. We provide evidence that during acute pancreatitis two different populations of exosomes are generated with relevant differences in cell distribution, protein and microRNA content as well as different implications in their physiological effects. During pancreatitis plasma exosomes, but not PAAF exosomes, are enriched in the inflammatory miR-155 and show low levels of miR-21 and miR-122. Mass spectrometry-based proteomic analysis showed that PAAF exosomes contains 10-30 fold higher loading of histones and ribosomal proteins compared to plasma exosomes. Finally, plasma exosomes have higher pro-inflammatory activity on macrophages than PAAF exosomes. These results confirm the generation of two different populations of exosomes during acute pancreatitis. Deep understanding of their specific functions will be necessary to use them as therapeutic targets at different stages of the disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy

  • Guillén Gómez, Elena|||0000-0002-8498-2579
  • Bardají de Quixano, Beatriz|||0000-0001-7456-355X
  • Ferrer, Sílvia
  • Brotons, Carlos|||0000-0001-9388-6581
  • Knepper, Mark A.
  • Carrascal Pérez, Montserrat|||0000-0002-0205-2176
  • Abian, Joaquin|||0000-0003-2823-5429
  • Mas, José M.
  • Calero, Francesca|||0000-0002-5758-0769
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Fernandez-Llama, Patricia|||0000-0002-7472-2124
Urinary proteome was analyzed and quantified by tandem mass tag (TMT) labeling followed by bioinformatics analysis to study diabetic nephropathy (DN) pathophysiology and to identify biomarkers of a clinical outcome. We included type 2 diabetic normotensive non-obese males with (n = 9) and without (n = 11) incipient DN (microalbuminuria). Sample collection included blood and urine at baseline (control and DN basal) and, in DN patients, after 3 months of losartan treatment (DN treated). Urinary proteome analysis identified 166 differentially abundant proteins between controls and DN patients, 27 comparing DN-treated and DN-basal patients, and 182 between DN-treated patients and controls. The mathematical modeling analysis predicted 80 key proteins involved in DN pathophysiology and 15 in losartan effect, a total of 95 proteins. Out of these 95, 7 are involved in both processes. VCAM-1 and neprilysin stand out of these 7 for being differentially expressed in the urinary proteome. We observed an increase of VCAM-1 urine levels in DN-basal patients compared to diabetic controls and an increase of urinary neprilysin in DN-treated patients with persistent albuminuria; the latter was confirmed by ELISA. Our results point to neprilysin and VCAM-1 as potential candidates in DN pathology and treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Rituximab, plasma exchange and immunoglobulins, an ineffective treatment for chronic active antibody-mediated rejection

  • Piñeiro, Gastón Julio|||0000-0003-3806-4731
  • De Sousa-Amorim, Erika
  • Solé, Manel|||0000-0003-0131-272X
  • Ríos, José|||0000-0002-0716-8784
  • Lozano, Miquel|||0000-0003-2593-833X
  • Cofan, Frederic|||0000-0003-4163-9620
  • Ventura-Aguiar, Pedro|||0000-0003-3381-7503
  • Cucchiari, David|||0000-0002-7594-1070
  • Revuelta, Ignacio|||0000-0002-3584-4516
  • Cid, Joan|||0000-0001-5445-4508
  • Palou, Eduard|||0000-0003-1544-1485
  • Campistol Plana, Josep M.|||0000-0002-6841-1119
  • Oppenheimer, Federico|||0000-0002-1117-831X
  • Rovira, Jordi|||0000-0001-8737-5005
  • Diekmann, Fritz|||0000-0001-6199-3016
Chronic active antibody-mediated rejection (c-aABMR) is an important cause of allograft failure and graft loss in long-term kidney transplants. To determine the efficacy and safety of combined therapy with rituximab, plasma exchange (PE) and intravenous immunoglobulins (IVIG), a cohort of patients with transplant glomerulopathy (TG) that met criteria of active cABMR, according to BANFF'17 classification, was identified. We identified 62 patients with active c-aABMR and TG (cg ≥ 1). Twenty-three patients were treated with the combination therapy and, 39 patients did not receive treatment and were considered the control group. There were no significant differences in the graft survival between the two groups. The number of graft losses at 12 and 24 months and the decline of eGFR were not different and independent of the treatment. A decrease of eGFR≥13 ml/min between 6 months before and c-aABMR diagnosis, was an independent risk factor for graft loss at 24 months (OR = 5; P = 0.01). Infections that required hospitalization during the first year after c-aABMR diagnosis were significantly more frequent in treated patients (OR = 4.22; P = 0.013), with a ratio infection/patient-year of 0.65 and 0.20 respectively. Treatment with rituximab, PE, and IVIG in kidney transplants with c-aABMR did not improve graft survival and was associated with a significant increase in severe infectious complications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease

  • Górriz, Jose Luis|||0000-0002-1134-9051
  • Arroyo, David|||0000-0003-4652-0311
  • D'Marco, Luis|||0000-0003-0148-891X
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Tomás, Patricia
  • Puchades, María Jesús
  • Panizo, Nayara|||0000-0002-1329-2976
  • Pantoja, Jonay
  • Montomoli, Marco|||0000-0003-1412-6352
  • Llisterri, José Luis
  • Pallarés Carratalá, Vicente|||0000-0002-2985-6078
  • Valdivielso, José Manuel|||0000-0003-1343-0184
Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent hereditary renal disease. There is an increased rate of cardiovascular disease (CVD) in ADPKD. In this study, we evaluate the prevalence of cardiovascular risk factors, the achievement rates for treatment goals and cardiovascular events (CVE) in ADPKD and their relations with asymptomatic CVD in CKD from other etiologies (CKDoe) and controls. We evaluated 2445 CKD patients (2010-2012). The information collected was: clinical, anthropometric and analytical parameters, treatments and CVD evaluation (intima-media thickness (IMT), atheromatous plaque presence and ankle-brachial index (ABI)). Laboratory, vital status, CVE and hospitalizations were collected for 4 years. ADPKD patients had a worse renal function and worst achievement of blood pressure, higher parathormone levels but lower proteinuria compared to CKDoe. ADPKD patients presented lower IMT values than other groups, however, an intermediate rate of pathologic ABI and atheromatous plaque was present. More than half of the patients received statins, achieving LDL-c levels < 100 only in 50 and 39.8% of them (ADPKD and CKDoe respectively). The number of CVE during the follow-up period was low. In adjusted Cox regression model, ADPDK had the lowest occurrence of CVE of all three groups (HR:0.422, 95%CI 0.221-0.808, p = 0.009). ADPKD patients show intermediate control rates of CVD. A better control of CVD risk seems to be related with a lower load of CVD compared to other groups, which may lead in the long term to a better prognosis. Further investigation is necessary to determine cardiovascular prognosis in ADPKD. The online version contains supplementary material available at 10.1186/s12882-021-02313-1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy

  • Fernández-Juárez, Gema|||0000-0001-6641-7763
  • Rojas-Rivera, Jorge E.|||0000-0003-2730-6328
  • Logt, Anne-Els van de
  • Justino, Joana
  • Sevillano Prieto, Angel Manuel|||0000-0001-9063-7037
  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Ávila, Ana
  • Rabasco, Cristina
  • Cabello, Virginia
  • Varela, Alfonso
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Martín-Reyes, Guillermo
  • Goicoechea, Marian|||0000-0002-7614-0830
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Gómez-Martino, Juan Ramón
  • Cao, Mercedes
  • Rodríguez-Moreno, Antolina
  • Rivas, Begoña|||0000-0002-5886-9943
  • Galeano Alvarez, Cristina|||0000-0003-2785-8886
  • Bonet Sol, Josep
  • Romera, Ana
  • Shabaka, Amir|||0000-0001-7039-4701
  • Plaisier, Emmanuelle
  • Espinosa, Mario
  • Egido de los Rios, Jesus
  • Segarra-Medrano, Alfonso
  • Lambeau, Gérard
  • Ronco, Pierre|||0000-0002-0280-6900
  • Wetzels, Jack
  • Praga, Manuel|||0000-0001-9270-1071
  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Trujillo, Hernando
  • Gutiérrez, Eduardo
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Verdalles, Úrsula
  • Segarra, Alfons
  • Perea, Lara
  • Valera, Ildefonso
  • Martín, Mónica
  • Pérez Valdivia, Miguel Angel
  • Blasco, Miquel Angel
  • López Muñiz, Andrés
  • Malek, Tamara
  • DaSilva Santos, Iara|||0000-0001-8203-6135
  • Bonet, Jordi
  • Navarro Diaz, Maruja Isabel|||0000-0003-3001-0595
  • Huerta, Ana|||0000-0003-3342-7628
  • Rodríguez-Paternina, Ezequiel
  • Vigil, Ana
  • Alcázar Arroyo, Roberto|||0000-0002-7433-3479
  • Paraíso, Vicente
  • Barrio, Vicente
  • Hofstra, Julia M.
A cyclical corticosteroid-cyclophosphamide regimen is recommended for patients with primary membranous nephropathy at high risk of progression. We hypothesized that sequential therapy with tacrolimus and rituximab is superior to cyclical alternating treatment with corticosteroids and cyclophosphamide in inducing persistent remission in these patients. This was tested in a randomized, open-label controlled trial of 86 patients with primary membranous nephropathy and persistent nephrotic syndrome after six-months observation and assigned 43 each to receive six-month cyclical treatment with corticosteroid and cyclophosphamide or sequential treatment with tacrolimus (full-dose for six months and tapering for another three months) and rituximab (one gram at month six). The primary outcome was complete or partial remission of nephrotic syndrome at 24 months. This composite outcome occurred in 36 patients (83.7%) in the corticosteroid-cyclophosphamide group and in 25 patients (58.1%) in the tacrolimus-rituximab group (relative risk 1.44; 95% confidence interval 1.08 to 1.92). Complete remission at 24 months occurred in 26 patients (60%) in the corticosteroid-cyclophosphamide group and in 11 patients (26%) in the tacrolimus-rituximab group (2.36; 1.34 to 4.16). Anti-PLA2R titers showed a significant decrease in both groups but the proportion of anti-PLA2R-positive patients who achieved immunological response (depletion of anti-PLA2R antibodies) was significantly higher at three and six months in the corticosteroid-cyclophosphamide group (77% and 92%, respectively), as compared to the tacrolimus-rituximab group (45% and 70%, respectively). Relapses occurred in one patient in the corticosteroid-cyclophosphamide group, and three patients in the tacrolimus-rituximab group. Serious adverse events were similar in both groups. Thus, treatment with corticosteroid-cyclophosphamide induced remission in a significantly greater number of patients with primary membranous nephropathy than tacrolimus-rituximab.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy

  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Rivero, Marta
  • Cavero Escribano, Teresa|||0000-0001-5187-9906
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Cabello, Virginia
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Barros, Xoana|||0000-0001-9690-9769
  • Ramos Terrades, Natalia|||0000-0001-9832-326X
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema|||0000-0001-6641-7763
  • Rodríguez Barba, Adela|||0000-0003-4382-3085
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez-Gómez, Maria Vanessa|||0000-0003-4558-5236
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia|||0000-0001-9857-793X
  • Sánchez de la Nieta, María Dolores
  • Rodríguez García, Eva
  • Olea, Teresa
  • Melgosa, Marta|||0000-0001-6236-414X
  • Huerta, Ana|||0000-0003-3342-7628
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • De Lorenzo, Alberto
  • Draibe, Juliana
  • González, Fayna
  • Shabaka, Amir|||0000-0001-7039-4701
  • López-Rubio, Maria Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, Luis
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago|||0000-0001-6401-1874
  • Goicoechea de Jorge, Elena|||0000-0002-4978-2483
  • Praga, Manuel|||0000-0001-9270-1071
Background: C3 glomerulopathy is a rare and heterogeneous complement-driven disease. It is often challenging to accurately predict in clinical practice the individual kidney prognosis at baseline. We herein sought to develop and validate a prognostic nomogram to predict long-Term kidney survival. Methods: We conducted a retrospective, multicenter observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. The dataset was randomly divided into a training group (n = 87) and a validation group (n = 28). The least absolute shrinkage and selection operator (LASSO) regression was used to screen the main predictors of kidney outcome and to build the nomogram. The accuracy of the nomogram was assessed by discrimination and risk calibration in the training and validation sets. Results: The study group comprised 115 patients, of whom 46 (40%) reached kidney failure in a median follow-up of 49 months (range 24-112). No significant differences were observed in baseline estimated glomerular filtration rate (eGFR), proteinuria or total chronicity score of kidney biopsies, between patients in the training versus those in the validation set. The selected variables by LASSO were eGFR, proteinuria and total chronicity score. Based on a Cox model, a nomogram was developed for the prediction of kidney survival at 1, 2, 5 and 10 years from diagnosis. The C-index of the nomogram was 0.860 (95% confidence interval 0.834-0.887) and calibration plots showed optimal agreement between predicted and observed outcomes. Conclusions: We constructed and validated a practical nomogram with good discrimination and calibration to predict the risk of kidney failure in C3 glomerulopathy patients at 1, 2, 5 and 10 years.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy

  • Caravaca-Fontan, Fernando|||0000-0002-5830-9663
  • Cavero Escribano, Teresa|||0000-0001-5187-9906
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Cabello, Virginia
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Quintana, Luis F.|||0000-0001-7582-8476
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Barros, Xoana|||0000-0001-9690-9769
  • Ramos Terrades, Natalia|||0000-0001-9832-326X
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema|||0000-0001-6641-7763
  • Rodríguez, Adela|||0000-0002-4899-6607
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez-Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia|||0000-0001-9857-793X
  • Sánchez de la Nieta, María Dolores
  • Rodríguez García, Eva
  • Rivas, Begoña|||0000-0002-5886-9943
  • Melgosa, Marta|||0000-0001-6236-414X
  • Huerta, Ana|||0000-0003-3342-7628
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • De Lorenzo, Alberto
  • Draibe, Juliana
  • González, Fayna
  • Shabaka, Amir|||0000-0001-7039-4701
  • López-Rubio, Maria Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, Luis
  • Da Silva, Iara
  • Titos, Juana Alonso
  • Rodríguez de Córdoba, Santiago|||0000-0001-6401-1874
  • Goicoechea de Jorge, Elena|||0000-0002-4978-2483
  • Praga, Manuel|||0000-0001-9270-1071
C3 glomerulopathy is a rare kidney disease, which makes it difficult to collect large cohorts of patients to better understand its variability. The aims of this study were to describe the clinical profiles and patterns of progression of kidney disease. This was a retrospective, observational cohort study. Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. Study population was divided into clinical profiles by combining the following predictors: eGFR under/above 30 ml/min per 1.73 m 2, proteinuria under/above 3.5 g/d, and histologic chronicity score under/above 4. The change in eGFR and proteinuria over time was evaluated in a subgroup with consecutive measurements of eGFR and proteinuria. One hundred and fifteen patients with a median age of 30 years (interquartile range 19-50) were included. Patients were divided into eight clinical profiles. Kidney survival was significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d, both in those presenting with an eGFR under/above 30 ml/min per 1.73 m 2. The median eGFR slope of patients who reached kidney failure was -6.5 ml/min per 1.73 m 2 per year (interquartile range -1.6 to -17). Patients who showed a reduction in proteinuria over time did not reach kidney failure. On the basis of the rate of eGFR decline, patients were classified as faster eGFR decline (≥5 ml/min per 1.73 m 2 per year), slower (<5 ml/min per 1.73 m 2 per year), and those without decline. A faster eGFR decline was associated with higher probability of kidney failure. Kidney survival is significantly higher in patients with a chronicity score <4 and proteinuria <3.5 g/d regardless of baseline eGFR, and a faster rate of decline in eGFR is associated with higher probability of kidney failure.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Evidence in chronic kidney disease-mineral and bone disorder guidelines, Is it time to treat or time to wait?

  • Bover, Jordi|||0000-0003-3577-2273
  • Ureña-Torres, Pablo|||0000-0001-6757-1906
  • Mateu, Silvia
  • DaSilva Santos, Iara|||0000-0001-8203-6135
  • Gràcia, Silvia
  • Sánchez-Baya, Maya|||0000-0003-1689-9383
  • Arana Aliaga, Carolt|||0000-0003-1100-5758
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Guirado, Luis|||0000-0001-5119-3912
  • Cozzolino, Mario|||0000-0002-8494-6252
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the many important complications associated with CKD and may at least partially explain the extremely high morbidity and mortality among CKD patients. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline document was based on the best information available at that time and was designed not only to provide information but also to assist in decision-making. In addition to the international KDIGO Work Group, which included worldwide experts, an independent Evidence Review Team was assembled to ensure rigorous review and grading of the existing evidence. Based on the evidence from new clinical trials, an updated Clinical Practice Guideline was published in 2017. In this review, we focus on the conceptual and practical evolution of clinical guidelines (from eMinence-based medicine to eVidence-based medicine and 'living' guidelines), highlight some of the current important CKD-MBD-related changes, and underline the poor or extremely poor level of evidence present in those guidelines (as well as in other areas of nephrology). Finally, we emphasize the importance of individualization of treatments and shared decision-making (based on important ethical considerations and the 'best available evidence'), which may prove useful in the face of the uncertainty over the decision whether 'to treat' or 'to wait'.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function

  • Guillén-Gómez, E.
  • Dasilva, I.
  • Silva, Irene|||0000-0002-2723-1031
  • Arce, Yolanda
  • Facundo, Carme|||0000-0003-1254-5553
  • Ars, Elisabet|||0000-0002-4118-4358
  • Breda, Alberto|||0000-0002-7842-9048
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Guirado, Luis|||0000-0001-5119-3912
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
Kidney transplants from living donors (LDs) have a better outcome than those from deceased donors (DDs). Different factors have been suggested to justify the different outcome. In this study, we analyzed the infiltration and phenotype of monocytes/macrophages and the expression of inflammatory and fibrotic markers in renal biopsy specimens from 94 kidney recipients (60 DDs and 34 LDs) at baseline and 4 months after transplantation. We evaluated their association with medium- and long-term renal function. At baseline, inflammatory gene expression was higher in DDs than in LDs. These results were confirmed by the high number of CD68-positive cells in DD kidneys, which correlated negatively with long-term renal function. Expression of the fibrotic markers vimentin, fibronectin, and α-smooth muscle actin was more elevated in biopsy specimens from DDs at 4 months than in those from LDs. Gene expression of inflammatory and fibrotic markers at 4 months and difference between 4 months and baseline correlated negatively with medium- and long-term renal function in DDs. Multivariate analysis point to transforming growth factor-β1 as the best predictor of long-term renal function in DDs. We conclude that early macrophage infiltration, sustained inflammation, and transforming growth factor-β1 expression, at least for the first 4 months, contribute significantly to the difference in DD and LD transplant outcome.